Zenas Biopharma Inc
ZBIO42.490USD
-0.680-1.58%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.79BMarket Cap
LossP/E TTM
More Details of Zenas Biopharma Inc Company
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Zenas Biopharma Inc Info
Ticker SymbolZBIO
Company nameZenas Biopharma Inc
IPO dateSep 13, 2024
CEOMoulder (Leon O)
Number of employees130
Security typeOrdinary Share
Fiscal year-endSep 13
Address1000 Winter St, Suite 1200
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone18572712954
Websitehttps://zenasbio.com/
Ticker SymbolZBIO
IPO dateSep 13, 2024
CEOMoulder (Leon O)
Company Executives of Zenas Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Haley Laken, Ph.D.
Dr. Haley Laken, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Leon O. Moulder, Jr.
Mr. Leon O. Moulder, Jr.
Founder, Chairman of the Board of Director, Chief Executive Officer
Founder, Chairman of the Board of Director, Chief Executive Officer
--
--
Mr. Joseph L. (Joe) Farmer, J.D.
Mr. Joseph L. (Joe) Farmer, J.D.
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Patricia Allen
Ms. Patricia Allen
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Business Officer, Chief Financial Officer
Chief Business Officer, Chief Financial Officer
--
--
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
Mr. Orlando Oliveira
Mr. Orlando Oliveira
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Haley Laken, Ph.D.
Dr. Haley Laken, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Leon O. Moulder, Jr.
Mr. Leon O. Moulder, Jr.
Founder, Chairman of the Board of Director, Chief Executive Officer
Founder, Chairman of the Board of Director, Chief Executive Officer
--
--
Mr. Joseph L. (Joe) Farmer, J.D.
Mr. Joseph L. (Joe) Farmer, J.D.
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Patricia Allen
Ms. Patricia Allen
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SR One Capital Management, LP
9.39%
InnoCare Pharma Inc.
9.31%
Fidelity Management & Research Company LLC
7.75%
Enavate Sciences GP, LLC
7.30%
Xencor Inc
5.77%
Other
60.48%
Shareholders
Shareholders
Proportion
SR One Capital Management, LP
9.39%
InnoCare Pharma Inc.
9.31%
Fidelity Management & Research Company LLC
7.75%
Enavate Sciences GP, LLC
7.30%
Xencor Inc
5.77%
Other
60.48%
Shareholder Types
Shareholders
Proportion
Venture Capital
30.14%
Corporation
25.57%
Investment Advisor
15.18%
Investment Advisor/Hedge Fund
9.57%
Hedge Fund
8.58%
Individual Investor
0.65%
Research Firm
0.08%
Bank and Trust
0.04%
Pension Fund
0.02%
Other
10.17%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
138
33.16M
73.18%
+2.06M
2025Q2
129
40.20M
96.10%
+6.07M
2025Q1
127
41.72M
100.11%
+9.15M
2024Q4
102
40.82M
97.67%
+11.84M
2024Q3
52
37.70M
93.71%
+37.70M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SR One Capital Management, LP
4.91M
11.66%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
3.09M
7.34%
+332.21K
+12.04%
Jun 30, 2025
Enavate Sciences GP, LLC
3.76M
8.93%
--
--
Jun 30, 2025
Xencor Inc
3.10M
7.36%
+3.10M
--
Sep 16, 2024
New Enterprise Associates (NEA)
2.73M
6.49%
+119.77K
+4.58%
Jun 30, 2025
Longitude Capital Management Co., LLC
2.50M
5.94%
+2.50M
--
Sep 16, 2024
Fairmount Funds Management LLC
1.89M
4.49%
--
--
Jun 30, 2025
Novo Holdings A/S
2.25M
5.34%
+35.03K
+1.58%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
1.86M
4.42%
+703.84K
+60.78%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.61%
ALPS Medical Breakthroughs ETF
0.54%
Fidelity Fundamental Small-Mid Cap ETF
0.19%
iShares Micro-Cap ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.07%
Vanguard US Momentum Factor ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 ETF
0.02%
Schwab U.S. Small-Cap ETF
0.02%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.61%
ALPS Medical Breakthroughs ETF
Proportion0.54%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.19%
iShares Micro-Cap ETF
Proportion0.1%
Fidelity Enhanced Small Cap ETF
Proportion0.07%
Vanguard US Momentum Factor ETF
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0.04%
Global X Russell 2000 ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zenas Biopharma Inc?
The top five shareholders of Zenas Biopharma Inc are:
SR One Capital Management, LP holds 4.91M shares, accounting for 11.66% of the total shares.
Fidelity Management & Research Company LLC holds 3.09M shares, accounting for 7.34% of the total shares.
Enavate Sciences GP, LLC holds 3.76M shares, accounting for 8.93% of the total shares.
Xencor Inc holds 3.10M shares, accounting for 7.36% of the total shares.
New Enterprise Associates (NEA) holds 2.73M shares, accounting for 6.49% of the total shares.
SR One Capital Management, LP holds 4.91M shares, accounting for 11.66% of the total shares.
Fidelity Management & Research Company LLC holds 3.09M shares, accounting for 7.34% of the total shares.
Enavate Sciences GP, LLC holds 3.76M shares, accounting for 8.93% of the total shares.
Xencor Inc holds 3.10M shares, accounting for 7.36% of the total shares.
New Enterprise Associates (NEA) holds 2.73M shares, accounting for 6.49% of the total shares.
What are the top three shareholder types of Zenas Biopharma Inc?
The top three shareholder types of Zenas Biopharma Inc are:
SR One Capital Management, LP
InnoCare Pharma Inc.
Fidelity Management & Research Company LLC
SR One Capital Management, LP
InnoCare Pharma Inc.
Fidelity Management & Research Company LLC
How many institutions hold shares of Zenas Biopharma Inc (ZBIO)?
As of 2025Q3, 138 institutions hold shares of Zenas Biopharma Inc, with a combined market value of approximately 33.16M, accounting for 73.18% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.93%.
What is the biggest source of revenue for Zenas Biopharma Inc?
In --, the -- business generated the highest revenue for Zenas Biopharma Inc, amounting to -- and accounting for --% of total revenue.
